AGLE
Aeglea BioTherapeutics Inc
Aeglea BioTherapeutics Inc
$AGLE Reports Q1 2023 Financial Results with $39.8 Million in Cash and Promising Clinical Programs
Aeglea BioTherapeutics' Q1 2023 financial results highlighted a cash and cash equivalents balance of $39.8m with development fee and royalty revenues of $0.2m and net loss of $18.4m. The revenue decline was related to lower activities related to its PEACE Phase 3 trial and Biologics License Application for pegzilarginase. Despite a decrease in revenues, Aeglea's focus on rare metabolic diseases and promising clinical programs make the report encouraging. However, investors should be cautious of risks and uncertainties outlined in the company's Safe Harbor/Forward Looking Statements.
4mo ago
$AGLE